Ruin Theory for Dynamic Spectrum Allocation in LTE-U Networks

LTE in the unlicensed band (LTE-U) is a promising solution to overcome the scarcity of the wireless spectrum. However, to reap the benefits of LTE-U, it is essential to maintain its effective coexistence with WiFi systems. Such a coexistence, hence, constitutes a major challenge for LTE-U deployment. In this paper, the problem of unlicensed spectrum sharing among WiFi and LTE-U system is studied. In particular, a fair time sharing model based on \emph{ruin theory} is proposed to share redundant spectral resources from the unlicensed band with LTE-U without jeopardizing the performance of the WiFi system. Fairness among both WiFi and LTE-U is maintained by applying the concept of the probability of ruin. In particular, the probability of ruin is used to perform efficient duty-cycle allocation in LTE-U, so as to provide fairness to the WiFi system and maintain certain WiFi performance. Simulation results show that the proposed ruin-based algorithm provides better fairness to the WiFi system as compared to equal duty-cycle sharing among WiFi and LTE-U.Comment: Accepted in IEEE Communications Letters (09-Dec 2018

The effect of endurance training on the level of tissue IL-6 and VEGF in mice with breast cancer

زمینه و هدف: تمرینات ورزش پتانسیلی در جهت پیشگیری از سرطان پستان دارد. هدف پژوهش حاضر بررسی اثرات پیشگیری و کمک درمانی تمرینات ورزشی بر سایتوکاین های درگیر در رگ زایی تومور سرطان پستان وابسته به گیرنده استروژن می باشد. روش بررسی: در این مطالعه مداخله ای 50 سر موش بالب سی ماده به طور تصادفی در چهار گروه قرار گرفتند. پس از آشناسازی با محیط دو گروه از موش ها به مدت 8 هفته تمرین استقامتی تداومی را انجام دادند و سپس سلول های سرطانی وابسته به استروژن (MC4-L2) به همه موش ها تزریق گردید. پس از آن یک گروه از موش های تمرین کرده و یک گروه از موش های تمرین نکرده به مدت 6 هفته، 5 روز در هفته تمرینات استقامتی را انجام دادند. حجم تومور به صورت هفتگی با کولیس دیجیتالی اندازه گیری شد. در پایان موش ها قربانی شدند و بافت تومور برداشته و سطوح سایتوکاین های اینترلوکین 6 (IL-6) و فاکتور رشد اپی تلیال عروق (VEGF) با روش الایزا اندازه گیری شد. یافته ها: بین گروه ها در میزان مقادیر IL-6 و VEGF و میزان رشد تومور تفاوت معناداری وجود داشت (001/0PP). نتیجه گیری: با توجه به افت مقادیر IL-6 و VEGF در گروه هایی که قبل از سرطانی شدن و پس از سرطانی شدن تمرینات ورزشی را انجام دادند؛ می توان گفت که تمرینات ورزشی علاوه بر نقش پیشگیرانه بسیار موثر، دارای نقش درمانی در تومورهای وابسته به گیرنده استروژن نیز می باشند

Evaluation of efficacy and safety of a polyherbal Unani formulation in diabetes mellitus type 2 (Zayābīṭus Sukkari Qism Sāni) - a randomised controlled clinical study

Diabetes mellitus type 2 (Zayābīṭus Sukkari Qism Sāni) is a major health concern in 21st century. Despite tremendousadvances in modern sciences, there is a lack of relatively safe and effective drug for its management.The primary objective of this study was to evaluate the efficacy and safety of a polyherbal Unani formulation containingGurmar booti (Gymnema sylvestre), Gilo (Tinospora cordifolia) and Jamun (Syzygium cumini) in the management of DiabetesMellitus Type 2 (DMT2). It was a randomised controlled clinical study conducted on 60 participants of DMT2 inadequatelycontrolled by diet and exercise. The test drug was given to group-A participants (n=30) 6 g twice daily orally for 12 weeks andthe standard drug metformin (500 mg) was given twice daily orally to group-B participants (n=30).It was observed that the difference between the Mean (± SD) value of fasting blood glucose (FBG), postprandial bloodglucose (PPBG) and glycosylated haemoglobin (HbA1c) in Test and Control groups at the end of the study in comparison tobaseline was significant (p<0.05). This study concludes that the test drug was effective in reducing FBG and PPBG significantlyin diabetic participants’ at 12 weeks of treatment

Evaluation of efficacy and safety of a polyherbal Unani formulation in diabetes mellitus type 2 (Zayābīṭus Sukkari Qism Sāni) - a randomised controlled clinical study

15-20Diabetes mellitus type 2 (Zayābīṭus Sukkari Qism Sāni) is a major health concern in 21st century. Despite tremendous advances in modern sciences, there is a lack of relatively safe and effective drug for its management. The primary objective of this study was to evaluate the efficacy and safety of a polyherbal Unani formulation containing Gurmar booti (Gymnema sylvestre), Gilo (Tinospora cordifolia) and Jamun (Syzygium cumini) in the management of Diabetes Mellitus Type 2 (DMT2). It was a randomised controlled clinical study conducted on 60 participants of DMT2 inadequately controlled by diet and exercise. The test drug was given to group-A participants (n=30) 6 g twice daily orally for 12 weeks and the standard drug metformin (500 mg) was given twice daily orally to group-B participants (n=30). It was observed that the difference between the Mean (± SD) value of fasting blood glucose (FBG), postprandial blood glucose (PPBG) and glycosylated haemoglobin (HbA1c) in Test and Control groups at the end of the study in comparison to baseline was significant (p<0.05). This study concludes that the test drug was effective in reducing FBG and PPBG significantly in diabetic participants’ at 12 weeks of treatment

Efficient Excitation of Micro/Nano Resonators and Their Higher Order Modes

We demonstrate a simple and flexible technique to efficiently activate micro/nano-electromechanical systems (MEMS/NEMS) resonators at their fundamental and higher order vibration modes. The method is based on the utilization of the amplified voltage across an inductor, L, of an LC tank resonant circuit to actuate the MEMS/NEMS resonator. By matching the electrical and mechanical resonances, significant amplitude amplification is reported across the resonators terminals. We show experimentally amplitude amplification up to twelve times, which is demonstrated to efficiently excite several vibration modes of a microplate MEMS resonator and the fundamental mode of a NEMS resonator

A Phase IB open-label, dose-escalation study of NUC 1031 in combination with carboplatin for recurrent ovarian cancer

Funding: The study was funded and the investigational drug NUC-1031 was supplied by NuCana plc.Purpose: NUC-1031 is a first-in-class ProTide modification of gemcitabine. In PRO-002, NUC‑1031 was combined with carboplatin in recurrent ovarian cancer (OC). Experimental Design: NUC-1031 was administered on days 1 & 8 with carboplatin on day 1 every 3 weeks for up to 6 cycles. Four dose cohorts of NUC-1031 (500, 625 and 750 mg/m2) with carboplatin (AUC4 or 5) were investigated. Primary endpoint was RP2CD. Secondary endpoints included safety, investigator-assessed objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS) and pharmacokinetics (PK). Results: 25 women with recurrent OC, a mean of 3.8 prior lines of chemotherapy and a median platinum-free interval (PFI) of 5 months (range: 7 - 451 days) were enrolled, 15/25 (60%) platinum-resistant; 9 (36%) partially platinum-sensitive and 1 (4%) platinum-sensitive. Of the 23 response-evaluable: there was 1 confirmed complete response (CR, 4%), 5 partial responses (PR, 17%) and 8 (35%) stable disease (SD). The ORR was 26% and CBR was 74% across all doses and 100% in the RP2CD cohort. Median PFS was 27.1 weeks. NUC-1031 was stable in the plasma and rapidly generated high intracellular dFdCTP levels that were unaffected by carboplatin. Conclusions: NUC-1031 combined with carboplatin is well tolerated in recurrent OC. Highest efficacy was observed at the RP2CD of 500 mg/m2 NUC-1031 on days 1 & 8 with AUC5 carboplatin day 1, every 3 weeks for 6 cycles. The ability to deliver carboplatin at AUC5 and the efficacy of this schedule even in patients with platinum-resistant disease makes this an attractive therapeutic combination.PostprintPeer reviewe

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

BACKGROUND: Src is involved in cancer invasion and metastasis. AZD0424, an oral inhibitor of Src and ABL1, has shown evidence of anti-tumour activity in pre-clinical studies. METHODS: A phase Ia, dose escalation study was performed to assess the safety of continuous oral dosing with AZD0424 in advanced solid tumours. Secondary objectives included investigation of AZD0424 pharmacokinetics, effect on Src activity using markers of bone turnover, and anti-tumour activity. RESULTS: 41 patients were treated; 34 received AZD0424 once-daily at doses ranging from 5 mg to 150 mg, and 7 received 40 mg bi-daily 41.5% of patients experienced at least one AZD0424-related adverse event that was Grade 3-5 in severity, with patients treated at doses above 60 mg per day experiencing multiple treatment-related toxicities. The most commonly observed AZD0424-related adverse events were nausea, fatigue, anorexia and alopecia. Cmaxand AUC increased linearly with dose and the mean±standard deviation t1/2was 8.4±2.8 h. Clear evidence of Src target inhibition was seen at doses ⩾20 mg per day. No responses were observed and 7 patients (17.1%) achieved stable disease lasting 6 weeks or more. CONCLUSIONS: AZD0424 displayed no evidence of efficacy as monotherapy despite a clear pharmacodynamic effect. Further evaluation of AZD0424 monotherapy in patients with solid tumours is not recommended

Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases

OBJECTIVES: The association of B cell targeted therapies with development of hypogammaglobulinaemia and infection is increasingly recognized. Our aim was to develop consensus recommendations for immunoglobulin replacement therapy for management of hypogammaglobulinaemia following B cell targeted therapies in autoimmune rheumatic diseases. // METHODS: A modified Delphi exercise involved a 17-member Taskforce committee, consisting of immunologists, rheumatologists, nephrologists, haematologists, a gastroenterologist, an immunology specialist nurse and a patient representative. The first round identified the most pertinent topics to address in the recommendations. A search string was agreed upon for the identification of publications in PubMed focusing on these areas, for a systematic literature review. Original data was presented from this review to the Taskforce committee. Recommendations from the British Society for Rheumatology, the UK Department of Health, EULAR, the ACR, and the American Academy of Allergy, Asthma, and Immunology were also reviewed. The evidence was discussed in a face-to-face meeting to formulate recommendation statements. The levels of evidence and statements were graded according to Scottish Intercollegiate Guidelines Network methodology. // RESULTS: Three overarching principles, eight recommendation statements and a research agenda were formulated. The Taskforce committee voted on these statements, achieving 82–100% agreement for each recommendation. The strength of the recommendations was restricted by the low quality of the available evidence, with no randomized controlled trial data. The recommendations cover risk factors, monitoring, referral for hypogammaglobulinaemia; indications, dosage and discontinuation of immunoglobulin replacement therapy. // CONCLUSION: These are the first recommendations specifically formulated for B cell targeted therapies related to hypogammaglobulinaemia in autoimmune rheumatic diseases. The recommendations are to aid health-care professionals with clinical decision making for patients with hypogammaglobulinaemia